130929-57-6 Usage
Description
Entacapone, also known as (E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-2-propenamide (Comtan), is a nitrocatechol derivative that is practically insoluble in water (pKa=4.50). It is a highly selective and orally-active catechol-O-methyltransferase (COMT) inhibitor, used as an adjunct to levodopa/carbidopa in the symptomatic treatment of patients with idiopathic Parkinson's Disease who experience the signs and symptoms of end-of-dose wearing off. Entacapone is rapidly absorbed after oral administration, does not cross the blood-brain barrier, and is completely metabolized before excretion. The main metabolic pathway is by isomerization to the cis-isomer followed by direct glucuronidation of the parent and the cis-isomer. The glucuronide conjugates are inactive. Entacapone is eliminated in the feces (90%) and urine (10%). It was introduced in Finland, Germany, and Sweden as an adjunctive treatment with L-dopa in Parkinson's disease.
Uses
Used in Pharmaceutical Industry:
Entacapone is used as a COMT inhibitor for the treatment of Parkinson's disease. It acts as a peripherally acting inhibitor of catechol-O-methyl transferase (COMT), an enzyme involved in the metabolism of catecholamine neurotransmitters and related drugs. By inhibiting the metabolism of L-dopa when given as an adjuvant in patients with Parkinson's disease, Entacapone markedly prolongs the effects of L-dopa and improves its bioavailability. Results from clinical studies showed that 200mg/day Entacapone coadministered with L-dopa lowered the dose of the latter required to reduce fluctuations in motor performance.
Entacapone is also used as an adjunct to levodopa/carbidopa in the symptomatic treatment of patients with idiopathic Parkinson's Disease who experience the signs and symptoms of end-of-dose wearing off. It belongs to the cinnamic acid amides, which are amides of cinnamic acids.
Chemical Properties:
Entacapone is a yellow crystalline solid.
Brand Names:
Comtan (Orion), Comtess.
Anti-Parkinson's disease drugs
Entacapone is an anti-Parkinson's disease drug which is successfully developed by Orion Pharma company in Swedish. It is a highly selective potent catechol-O-methyltransferase (COMT) inhibitor, rarely penetrating the blood-brain barrier, and primarily acting in the intestinal tract. It is dose-dependent to decrease levels of 3-OMD in serum and the brain, increasing levodopa, dopamine and DOPAC levels in the brain and significantly reducing the dose which is required to increase dopamine concentration in striatal. Levodopa and carbidopa combining with COMTI can significantly increase the bioavailability of levodopa (3-4 times). Activity of COMTI in red blood cell is reversible. When in 800mg dose, the maximum inhibitory activity is up to 82%, so Entacapone combines with levodopa and carbidopa, which can be used for adjuvant therapy of idiopathic Parkinson's disease.
Pharmacokinetics
This product is rapid oral absorption, the bioavailability is a dose-dependent with the range of 30% to 45%. In the range of 5~800 mg, pharmacokinetics of Entacapone (abbreviation: Ent) is linear, peak plasma concentration is related to AUC and dose. Food does not affect the absorption of this product, 98% Ent combines with plasma albumin, rarely distributing in tissues. In patients with Parkinson disease (abbreviated: PD), and is required to take levodopa/carbidopa, the peak concentration of Ent arrives within 1~2h. The rate of Ent through the blood-brain barrier is low, the plasma elimination half-life is 1.5~3.5h. After oral administration, Ent (E-configuration) is metabolized to Z-isomer in the blood and is present in plasma and red blood cells. Z-isomer has little impact on the clinical efficacy. Its drug-time curve is similar to Ent. Z-Ent accounts for about 5% of the total AUC. Ent and Z-Ent are acidified by glucose in the liver. After metabolism of Ent: 10% excreted in the urine, 90% of Ent excreted in the feces, only 0.2% excreted in the urine in phony drugs. While taking levodopa in PD patients, and oral Ent 200 mg after elimination half-life of about 1 h, the body has no savings.
Pharmacokinetic study shows that in healthy persons and patients with PD, Ent can increase the bioavailability of levodopa. In the short-term PD patients taking Ent, AUC of levodopa increase 25%, while the long-term taking Ent can increase 50%. AUC of 3-OMD relatively reduces 60%. In these studies, they found that plasma peak time of levodopa will be extended. Single dose of Entacapone (while not taking levodopa/carbidopa), in patients with liver disease, the patient's AUC and Cmax is 2 times of the patients with normal liver function. We should adjust the dosage of the patient. In patients with mild to moderate kidney disease, it is not necessary to adjust the dosage. Kidney patients receiving dialysis can extend dosing interval.
The above information is edited by the lookchem of Liu Yujie.
Chemical property
Crystals, melting point 162--163 ℃.
Production method
1.83 g 3,4-dihydroxy-5-nitrobenzaldehyde and 1.5g N, N-diethyl-cyanoacetamide and a catalytic amount of piperidine acetate are dissolved in 40ml of dry ethanol , followed by stirring overnight , 2.23 g crude product is obtained, yield 73%, melting point 153~156 ℃.
Heated at 90 ℃, the 3.0 kg crude product is dissolved in 8.0kg acetic acid (or formic acid) containing 80 g HBr (or 40gHCl).It is slowly cooled to 20 ℃, and stirred at this temperature for 20h, then at 15 ℃ stirred for 6h. The precipitated crystals were collected by filtration, carefully washed with cool (4 ℃) 1L toluene-acetic acid (1: l v/v) mixed solution, and washed with 1L cold toluene. It is dried at 45 ℃under vacuum and 2.4kg crystalline pure Entacapone is obtained, yield 80%, melting point 162-163 ℃.
Originator
Orion Pharma (Finland)
Therapeutic Function
Antiparkinsonian
Biochem/physiol Actions
Entacapone is a catechol-O-methyl transferase (COMT) inhibitor. Used in treatment of Parkinson′s disease, entacapone is administered with L-DOPA to inihibit COMT from converting L-DOPA into a compound that cannot cross the blood brain barrier.
Clinical Use
#N/A
Drug interactions
Potentially hazardous interactions with other drugs Anticoagulants: enhances anticoagulant effect of
warfarinAntidepressants: use with caution in combination
with moclobemide, tricyclics and venlafaxine; avoid
with MAOIs. Dopaminergics: possibly enhances effects of
apomorphine; possibly reduces concentration
of rasagiline; max dose of selegiline is 10 mg in
combination.
Metabolism
Entacapone undergoes extensive first-pass metabolism to
form glucuronide metabolites.It is eliminated mainly in the faeces with about 10-20%
being excreted in the urine, mainly as glucuronide
conjugates
References
1) Forsberg?et al.?(2003),?Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat; J. Pharmacol. Exp. Ther.,?304?498
2) Merello?et al. (1994),?Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson’s disease; J. Neurol. Neurosurg. Psychiatry,?57?186
3) Giovanni?et al. (2010),?Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of alpha-synuclein and beta amyloid and protect against amyloid-induced toxicity; J. Biol. Chem.,?285?14941
4) Chen?et al. (2016),?Entacapone is an Antioxident More Potent than Vitamin C and Vitamin E for Scavenging of Hypochlorous Acid and Peroxynitrite, and the Inhibition of Oxidative Stress-induced Cell Death; Med. Sci. Monit.,?22?687
Check Digit Verification of cas no
The CAS Registry Mumber 130929-57-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,0,9,2 and 9 respectively; the second part has 2 digits, 5 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 130929-57:
(8*1)+(7*3)+(6*0)+(5*9)+(4*2)+(3*9)+(2*5)+(1*7)=126
126 % 10 = 6
So 130929-57-6 is a valid CAS Registry Number.
InChI:InChI=1/C14H15N3O5/c1-3-16(4-2)14(20)10(8-15)5-9-6-11(17(21)22)13(19)12(18)7-9/h5-7,18-19H,3-4H2,1-2H3/b10-5+
130929-57-6Relevant articles and documents
Synthesis of entacapone by Pd-catalyzed heck coupling reaction
Veerareddy, Arava,Reddy, Gogireddy Surendra
, p. 1274 - 1278 (2014)
Synthesis of entacapone from 4-iodo-2-methoxy-phenol with 2-cyano-N,N-diethylacrylamide by palladium-catalyzed Heck reaction, as a key step, is described.
Entacapone preparation method
-
, (2018/09/13)
The invention relates to an entacapone preparation method, which comprises: carrying out condensation on 3-alkoxy-4-hydroxybenzaldehyde and cyanoacetic acid to generate an intermediate 2-cyano-acrylicacid (III), carrying out a reaction on the compound (III) and a halogenating agent to generate an acyl halide (IV), carrying out a reaction on the acyl halide (IV) and diethylamine to generate the salt (V) of entacapone alkyl ether, and carrying out acidolysis demethylation on the salt (V) in a suitable solvent to generate entacapone (I). According to the present invention, the method has characteristics of convenient operation, mild reaction conditions and high in yield, and is suitable for large-scale industrial production. The formulas (I), (III), (IV) and (V) are defined in the specification.
Novel triethylamine mediated thermal reactions of 3-aryl-2-cyanoprop-2-enoic acid derivatives - Demethylation, reduction and vinylogation
Harisha, Attimogae Shivamurthy,Nayak, Suresh Parameshwar,Nagarajan, Kuppuswamy,Guru Row, Tayur Narasingarow,Hosamani, Amar A.
supporting information, p. 1427 - 1431 (2015/03/04)
3-Aryl-2-propenoic acid derivatives undergo interesting reactions with hot triethylamine. Substrates like 6 having a methoxyl with a nitro in the ortho and cyanoacrylic derivatives in the para positions give O-demethylated products, for example, entacapone 7. On the other hand compounds like 16 having the NO2 in the para and cyanoacrylic in the ortho position undergo reduction and vinylogation. The latter phenomenon is observed in the absence of the NO2 group also.